Plus: ACOG revises postmenopausal bleeding guidance, FDA-cleared AID tech for T1D pregnancies, and South Africa's first generic hormonal IUD
Organon's $11.75B sale to Sun Pharma is the largest women's health pharmaceutical deal of the year and reshapes the global contraceptive and maternal health pipeline. Meanwhile, FDA actions on AID technology and ACOG's revised postmenopausal bleeding guidance signal where standard-of-care is heading for menopause and pregnancy care. Five takes inside, plus a quick-hits roundup.
India’s largest pharmaceutical company, Sun Pharmaceutical Industries, will acquire Organon in an all-cash transaction valued at $11.75 billion. Organon, a major women’s health pharmaceutical company, will provide stockholders with $14.00 per share. The acquisition is expected to close in early 2027.
Read the full story →Medicines360 and Pharma Dynamics launched Avibela, South Africa’s first generic levonorgestrel 52 mg intrauterine device. Avibela is over 99% effective at preventing pregnancy for up to six years and treats heavy menstrual bleeding. This launch addresses an access gap for approximately nine million women in South Africa.
Read the full story →ACOG now recommends a combination of transvaginal ultrasonography and endometrial tissue sampling for the initial evaluation of most patients presenting with postmenopausal bleeding. This guidance updates standard practice for women's health in the menopause and gynecology fields.
Read the full story →New research reveals significant disparities in the immediate administration of STI antibiotics within emergency departments. These differences are influenced by a patient's pregnancy status.
Read the full story →Rachel Sood discussed the clinical impact of FDA-cleared AID technology in pregnancy. The FDA clearance of Control-IQ+ provides clinical proof for expanding the use of AID systems in T1D pregnancies.
Read the full story →